BioSpace News Archive

Precision Molecular, Inc. today announced it has executed a licensing agreement with Johns Hopkins University for exclusive rights to an astatine-211-labeled inhibitor of prostate-specific membrane antigen (PSMA) which is typically elevated in prostate cancer cells.

Precision BioSciences, Inc. today announced that it has entered into an agreement with a syndicate of investors led by ACCELR8 to separate its wholly owned Elo Life Systems subsidiary and create an independent food and agriculture business.

XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences:

Achilles Therapeutics plc announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET.

Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant, will present a company update as part of the 40th Annual J.P Morgan Healthcare Conference.

Allarity Therapeutics, Inc. announced the closing of its Recapitalization Share Exchange resulting in its initial public listing of 8,075,824 shares of its common stock and listing on the U.S Nasdaq Stock Market under the trading symbol “ALLR.”.

Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that it has submitted a New Drug Application (J-NDA) to the Japanese Ministry of Health, Labour & Welfare (MHLW) for the marketing approval of FINTEPLA® (fenfluramine) for the treatment of epileptic seizures associated with Dravet syndrome in Japan.

Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug CyclASol® for the treatment of dry eye disease (DED).

PerkinElmer, Inc. today announced that the Company will present virtually at the annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 11:15 a.m. ET.

NanoVibronix Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield® and PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that it has commenced sales in Europe with the signing of a distribution agreement with Medina Healthcare Ltd (“Medina”) in Malta.